INTERVENTIONALAuthorised2024-514783-78-00
BOOSTCAMP - Boosting the endocannabinoid system before the treatment of anxiety symptoms
to examine the effects of a 2-week administration of Cannabidiol (CBD) in alleviating anxiety symptoms before anxiety or PTSD treatments in Dutch uniformed personnel
Locally preserved from EU Clinical Trials Information SystemOpen EU Clinical Trials Information System↗last source update 2026-08-22
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- PHASEII
- Enrollment
- 82 (ACTUAL OR ANTICIPATED)
- Start date
- 2024-10-29
- Sponsor
- Universitair Medisch Centrum Utrecht
- Design
- Not reported
- Locations
- 0
- Results record
- Not present in registry snapshot
This study investigates the effects and safety of CBD in a clinical population
psychological disorders: PTSD; Anxiety disorderspsychological disorders: PTSD; Anxiety disorders
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Cannabinoids and active compounds
No governed compound link was found.
Medicines
No exact medicine-name link was found.
Interventions
What was registered
No structured intervention was reported.
Eligibility
Population and criteria
- Sex
- Not reported
- Minimum age
- Not reported
- Maximum age
- Not reported
- Healthy volunteers
- Not reported
Eligibility criteria
- ['Dutch uniformed personnel, which are (former) police-officers, firefighters, ambulance paramedics, military personnel or veterans.', 'Age between 18-65', 'Waiting for therapy for the treatment of a trauma and stressor-related and/or an anxiety disorder (as determined by the MINI PLUS psychiatric interview)'] ['Severe co-morbidity (severe major depressive or bipolar disorder and/or psychosis)', 'Alcohol and/or drug dependence', 'Inability to adequately read or speak Dutch', '(a history of) epilepsy or brain damage, cardiac, renal or liver abnormalities', '(a history of) allergies to medication (adverse reactions or rash)', 'Individuals taking certain medications known to have potential interactions with CBD (i.e., steroids, HMG-CoA reductase inhibitors, calcium channel blockers, antihistamines, antivirals, immune modulators, benzodiazepines, anti-arrhythmic, antibiotics, anesthetics, antipsychotics, antidepressants, anti-epileptics, beta blockers, proton pump inhibitors, NSAIDs, angiotensin II blockers, oral hypoglycemic agents, and sulfonylureas)', 'Used cannabis, synthetic cannabinoid, cannabinoid analogue, or any CBD or THC-containing product within 30 days of eligibility screening.', 'Individuals that had been diagnosed with intestinal, liver, or renal diseases that would affect absorption or clearance of CBD', 'For women: pregnant, a wish to become pregnant, or nursing']
Publications
Locally readable linked articles
0No exact PMID-linked public article is currently readable locally.
Snapshot provenance
- Snapshot
- 176de592-e2d4-4159-bfa1-c5c8e72c3526
- Retrieved
- 25/08/2026, 17:13:07
- SHA-256
- bbbbe6211266aeac6a2603a803c725c847998c459ee86ecde98492accc7dcf42